DelveInsight’s “Esophageal Cancer Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Esophageal Cancer market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Esophageal Cancer drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Esophageal Cancer treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Esophageal Cancer: An Overview
Esophageal Cancer is a disease in which malignant (cancer) cells form in the tissues of the esophagus, which starts when cells in the esophagus lining begin to grow out of control. According to the World Cancer Research Fund International (WCRF), Esophageal Cancer is the eighth most common cancer worldwide – the seventh most common cancer in men and the thirteenth most common cancer in women.
Esophageal Cancer has been identified as a serious public health issue that requires immediate attention due to changes in the predominant type of squamous cell carcinoma (SCC) to adenocarcinoma, disparities between different ethnic groups, and the exponential rise in incidence rates of adenocarcinoma. In particular, Esophageal Cancer starts in the inner layer of the esophageal wall and spreads outward. In some situations, it can spread to neighboring lymph nodes and, in severe cases, even to other organs like the lungs, liver, and stomach.
In contrast to ESCC, EAC’s major somatic genetic anomalies revealed a distinct genetic environment. Copy number changes, a high mutational burden, co-amplification of receptor tyrosine kinase, and frequent TP53 mutations are the main characteristics of the heterogeneous cancer EAC.
Esophageal Cancer Market Key Facts
-
The total diagnosed incident cases of Esophageal Cancer in the 7MM comprised ~75,600 cases in 2022 and are projected to increase by 2032 with a significant CAGR.
-
As per the DelveInsight estimates, in the 7MM the highest number of diagnosed incident cases of Esophageal Cancer were observed in Japan, followed by the US and the UK.
-
In 2022, total histology-specific cases of Esophageal Cancer were ~7,400 and ~12,700 cases for squamous and non-squamous Esophageal Cancer, respectively, in the US, which are projected to increase by 2032. In the US, most histology-specific cases were squamous Esophageal Cancer due to the rising number of cases of its associated risk factors.
-
According to the Centers for Disease Control and Prevention (CDC) (2022), there were 18,950, 18,669, and 18,090 new cases of Esophageal Cancer in 2019, 2018, and 2017, respectively. The CDC reported the number of Esophageal Cancer cases from 1999 to 2019. The year-on-year growth was calculated from these numbers, which were used to project the diagnosed incident cases till 2032.
-
According to the National Cancer Center Japan – GANJOHO (2022), there were 26,382 newly diagnosed cases of Esophageal Cancer in 2019.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Esophageal Cancer pipeline therapies. It also thoroughly assesses the Esophageal Cancer market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Esophageal Cancer drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Esophageal Cancer Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Esophageal Cancer epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Esophageal Cancer epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Esophageal Cancer Epidemiology, Segmented as –
-
Total Diagnosed Incident Cases of Esophageal Cancer in the 7MM [2019–2032]
-
Line-wise Treated Cases of Esophageal Cancer in the 7MM [2019–2032]
-
Gender-specific Cases of Esophageal Cancer in the 7MM [2019–2032]
-
Histology-specific Cases of Esophageal Cancer in the 7MM [2019–2032]
-
Age-specific Cases of Esophageal Cancer in the 7MM [2019–2032]
-
Mutation-specific Cases of Esophageal Cancer in the 7MM [2019–2032]
-
Stage-specific Cases of Esophageal Cancer in the 7MM [2019–2032]
Esophageal Cancer Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Esophageal Cancer market or expected to be launched during the study period. The analysis covers the Esophageal Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Esophageal Cancer drugs based on their sale and market share.
The report also covers the Esophageal Cancer pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Esophageal Cancer companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Esophageal Cancer Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/esophageal-cancer-market
Esophageal Cancer Therapeutics Analysis
Treatment of esophageal cancer depends on many factors, including the stages of cancer. A patient with stage 0 esophageal cancer may have surgery, photodynamic therapy, radiofrequency ablation, or endoscopic mucosal resection. A patient with stage I, II, and III esophageal cancer may have surgery, chemotherapy, or radiation. Whereas, a patient with stage IV esophageal cancer may have Chemotherapy, radiation, targeted therapy, or immunotherapy; treatment for this stage focuses on “palliative” therapy.
Targeted therapies include drugs like trastuzumab (Herceptin, OGIVRI) which may be used along with chemotherapy as a first treatment for metastatic esophageal adenocarcinoma. Trastuzumab deruxtecan (ENHERTU) is also approved as the first treatment for metastatic esophageal adenocarcinoma. Ramucirumab (CYRAMZA) is recommended as a treatment option in combination with paclitaxel chemotherapy for advanced gastroesophageal or gastroesophageal junction adenocarcinoma if first-line therapy has not worked. Further immunotherapies include Pembrolizumab (KEYTRUDA) and Nivolumab (OPDIVO); checkpoint inhibitors target the PD-1/PD-L1 pathway.
Currently, six drugs are approved for the treatment of esophageal cancer. To further improve the treatment outlook, several major pharma and biotech companies developing therapies for Esophageal Cancer. Currently, Seagen is leading the therapeutics market with its Esophageal Cancer drug candidates in the most advanced stage of clinical development.
Esophageal Cancer Companies Actively Working in the Therapeutics Market Include
BeiGene, AstraZeneca, CSPC ZhongQi Pharmaceutical Technology, Amgen, Jiangsu Hengrui Medicine, Oncolys Biopharma, Pfizer, Novartis, Luye Pharma, Eli Lilly and Company, ImmunoFrontier, Inc, Adaptimmune, Innovent Biologics (Suzhou) Co. Ltd., Genentech, Janssen Pharmaceuticals, Merck KGaA, Shenzhen Hornetcorn Biotechnology, Apexigen, Inc., Highlight Therapeutics, EMD Serono, HaiHe Biopharma, Lumicell, Jacobio Pharmaceuticals Co., Ltd., TESARO, Ascentage Pharma Group Inc.,, Adlai Nortye, Seagen, and others.
Emerging and Marketed Esophageal Cancer Therapies Covered in the Report Include:
-
AN-0025: Adlai Nortye
-
Tucatinib: Seagen
-
APX 005M: Apexigen
And Many Others
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/esophageal-cancer-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Esophageal Cancer Competitive Intelligence Analysis
4. Esophageal Cancer Market Overview at a Glance
5. Esophageal Cancer Disease Background and Overview
6. Esophageal Cancer Patient Journey
7. Esophageal Cancer Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Esophageal Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Esophageal Cancer Unmet Needs
10. Key Endpoints of Esophageal Cancer Treatment
11. Esophageal Cancer Marketed Therapies
12. Esophageal Cancer Emerging Drugs and Latest Therapeutic Advances
13. Esophageal Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Esophageal Cancer Market Outlook (In US, EU5, and Japan)
16. Esophageal Cancer Companies Active in the Market
17. Esophageal Cancer Access and Reimbursement Overview
18. KOL Views on the Esophageal Cancer Market
19. Esophageal Cancer Market Drivers
20. Esophageal Cancer Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/esophageal-cancer-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Dravet Syndrome Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Dravet Syndrome market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Dravet Syndrome market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research